Janus Henderson Group PLC Grows Position in Halozyme Therapeutics, Inc. $HALO

Janus Henderson Group PLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 42.8% during the 1st quarter, HoldingsChannel reports. The firm owned 1,233,658 shares of the biopharmaceutical company’s stock after acquiring an additional 369,702 shares during the period. Janus Henderson Group PLC’s holdings in Halozyme Therapeutics were worth $79,742,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership lifted its position in Halozyme Therapeutics by 29.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock valued at $241,337,000 after buying an additional 749,484 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Halozyme Therapeutics by 1.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock worth $141,613,000 after buying an additional 25,731 shares during the period. Norges Bank bought a new position in shares of Halozyme Therapeutics in the 4th quarter worth about $128,201,000. William Blair Investment Management LLC bought a new position in shares of Halozyme Therapeutics in the 4th quarter worth about $124,031,000. Finally, Federated Hermes Inc. lifted its position in Halozyme Therapeutics by 8.5% during the 4th quarter. Federated Hermes Inc. now owns 1,574,621 shares of the biopharmaceutical company’s stock valued at $105,972,000 after acquiring an additional 123,917 shares during the period. Institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling

In other Halozyme Therapeutics news, CEO Helen Torley sold 1,923 shares of the business’s stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $79.77, for a total value of $153,397.71. Following the completion of the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $61,245,810.60. The trade was a 0.25% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the transaction, the director owned 14,462 shares in the company, valued at $1,084,650. This represents a 33.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 72,477 shares of company stock worth $5,102,643. 2.50% of the stock is owned by corporate insiders.

Halozyme Therapeutics Stock Down 0.9%

Shares of Halozyme Therapeutics stock opened at $82.54 on Friday. The company has a 50-day simple moving average of $74.52 and a two-hundred day simple moving average of $70.93. The stock has a market capitalization of $9.79 billion, a PE ratio of 29.69, a price-to-earnings-growth ratio of 0.35 and a beta of 0.84. Halozyme Therapeutics, Inc. has a 52-week low of $58.53 and a 52-week high of $84.44. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. The company had revenue of $376.71 million during the quarter, compared to analyst estimates of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm’s revenue for the quarter was up 42.2% on a year-over-year basis. During the same period in the previous year, the business earned $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, analysts anticipate that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on HALO. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. HC Wainwright reissued a “buy” rating and issued a $95.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Finally, Morgan Stanley cut their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. Eight equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $81.60.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.